Title : Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.

Pub. Date : 2021 Oct

PMID : 33991350






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Being a cytochrome P450 (CYP) 3A substrate, pharmacokinetic interactions of bedaquiline are anticipated with clarithromycin (a CYP3A inhibitor), which is routinely used in PNTM treatment. Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 Being a cytochrome P450 (CYP) 3A substrate, pharmacokinetic interactions of bedaquiline are anticipated with clarithromycin (a CYP3A inhibitor), which is routinely used in PNTM treatment. Clarithromycin cytochrome P450 family 3 subfamily A member 4 Homo sapiens